Muscle Spasticity - Pipeline Insight, 2024

Muscle Spasticity - Pipeline Insight, 2024

DelveInsight’s, Muscle Spasticity - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Muscle Spasticity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Muscle Spasticity Understanding

Muscle Spasticity: Overview

Spasticity, which is sometimes referred to as tightness or stiffness, is a motor disorder marked by a velocity-dependent increase in muscle tone or tonic stretch reflexes associated with hypertonia. Colloquially, it is often referred to as “tightness” or “stiffness.” Spasticity can present variably in a clinical setting, sometimes with a subtle neurological manifestation and, other times, with severely increased muscle tone leading to immobility of joints. Spasticity can lead to many complications, including but not limited to, interference with daily function, hygiene, comfort, and nursing care as well as contractures, increasing the risk of pressure ulcers and subsequent infections. Also, spasticity poses an increased risk of subluxation and/or dislocation as well as heterotopic ossification. Spasticity is considered to be a positive sign of the upper motor neuron syndrome (UMNS), which refers to motor behaviors resulting from lesions proximal to the alpha motor neuron, therefore within the spinal cord or brain. Other positive features of UMNS include exaggerated muscle stretch reflexes and up-going plantar reflexes. Negative features include motor weakness, slowed movement, loss of dexterity, or selective motor control. A UMN injury leads to loss of inhibition downstream and hypersensitivity of the reflex arc within the spinal cord. Many clinical scenarios can lead to spasticity, such as stroke, cerebral palsy (CP), anoxia, traumatic brain injury (TBI), spinal cord injury (SCI), multiple sclerosis (MS), and other neurodegenerative diseases.

""Muscle Spasticity - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Muscle Spasticity pipeline landscape is provided which includes the disease overview and Muscle Spasticity treatment guidelines. The assessment part of the report embraces, in depth Muscle Spasticity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Muscle Spasticity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Muscle Spasticity. The therapies under development are focused on novel approaches to treat/improve Muscle Spasticity.

Muscle Spasticity Emerging Drugs

Arbaclofen ER: Janssen Pharmaceutical

Arbaclofen ER is an extended release formulation of arbaclofen, the R isomer of baclofen, that leverages our proprietary Osmodex® drug delivery system and is being studied for the treatment of spasticity resulting from multiple sclerosis.

Lu AG06466: Abide Therapeutics

Lu AG06466 (formerly ABX 1431) is an oral, small molecule, being developed by Abide Therapeutics (now Lundbeck A/S), for the treatment of neuropathic pain, pain in irritable bowel syndrome, multiple sclerosis associated spasticity [muscle spasticity in the development table], fibromyalgia and epilepsy.

Further product details are provided in the report……..

Muscle Spasticity: Therapeutic Assessment

This segment of the report provides insights about the Muscle Spasticity drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Muscle Spasticity

There are approx. 15+ key companies which are developing the therapies Muscle Spasticity. The companies which have their Muscle Spasticity drug candidates in the most advanced stage, i.e preregistration include RVL Pharmaceuticals

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Muscle Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Muscle Spasticity: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Muscle Spasticity therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Muscle Spasticity drugs.

Muscle Spasticity Report Insights

• Muscle Spasticity Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Muscle Spasticity Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Muscle Spasticity drugs?
• How many Muscle Spasticity drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Muscle Spasticity?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Muscle Spasticity therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Muscle Spasticity and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Saol Therapeutics
• Daewoong Pharmaceutical
• AbbVie
• Supernus Pharmaceuticals
• Revance Therapeutics
• Ipsen
• Abide Therapeutics
• Motor Pharma
• BetterLife Pharma
• RVL Pharmaceuticals

Key Products

• SIL 1002
• Prabotulinumtoxin A
• Onabotulinum toxin A
• Botulinum toxin B
• Daxibotulinumtoxin A
• Botulinum toxin A
• Botulinum toxin A longer acting
• Lu AG06466
• MPH 220
• BETR 002
• Arbaclofen extended release